Stockreport

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Aclaris Therapeutics, Inc.  (ACRS) 
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: aclaristx.com
PDF - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - - Trial Res [Read more]